Drug eluting patch for the treatment of localized tissue disease or defect

Patent metadata

Field	Value
Publication number	US-9532943-B2
Application number	US-201113328287-A
Country	US
Kind code	B2
Filing date	Dec 16, 2011
Priority date	Dec 20, 2010
Publication date	Jan 3, 2017
Grant date	Jan 3, 2017

Abstract

A polymeric matrix for delivery of an HMG CoA reductase inhibitor such as a statin to tissue such as cardiac tissue in need thereof for the treatment or prevention of a disease or defect such as atrial fibrillation has been developed. In the preferred embodiment, a statin is delivered by means of a patch sutured to cardiac tissue at the time of cardiothoracic surgery. In the most preferred embodiment, the patch is a biodegradable material providing controlled or sustained release over a prolonged period of time, such as a week. Suitable materials include extracellular matrix, or other biodegradable hydrogels or polymeric materials providing sustained or controlled release of statin at the site of application.

First claim

We claim:

1. A patch for treating a cardiac disorder, comprising:
a matrix comprising acellular extracellular matrix (ECM); and
a HMG CoA reductase inhibitor comprising cerivastatin, said cerivastatin comprising in the range of 10 μg/cm 2 -10 mg/cm 2 of said ECM matrix,
said ECM matrix being capable of modulating inflammation of post-operative cardiac tissue when administered thereto, said inflammation modulation comprising inhibiting localized expression of monocyte chemoattractant protein 1 (MCP-1) and C-C chemokine receptor type 2 (CCR2).

2. The patch of claim 1 , wherein said HMG CoA reductase inhibitor is dispersed within said ECM matrix.

3. The patch of claim 1 , wherein said ECM matrix is in the form of a graft.

4. The patch of claim 1 , wherein said ECM matrix is configured to be applied as a spray.

5. The patch of claim 1 , wherein said ECM matrix is configured to be applied as a biological glue.

6. The patch of claim 1 , wherein said ECM matrix further includes a pharmacological agent component comprising an anti-thrombotic agent.

7. The patch of claim 1 , wherein said ECM matrix is in the form of a hydrogel.

8. The patch of claim 1 , wherein said ECM matrix is in the form of a woven matrix.

9. The patch of claim 1 , wherein said ECM matrix is in the form of a non-woven matrix.

10. A method for treating tissue injury or defect comprising administering to or near the patch the device of claim 1 .

11. The method of claim 10 wherein the tissue injury or defect is caused by ischemia.

12. The method of claim 10 wherein the tissue is cardiac tissue and the defect is atrial fibrillation.

13. The method of claim 10 wherein the patch is administered during surgery.

14. The method of claim 10 wherein the patch is administered through a catheter or as part of a stent.

Assignees

• Matheny Robert
• Cormatrix Cardiovascular Inc

Inventors

• Matheny Robert

Classifications

• A61F2/042

  Urinary bladders · CPC title

• A61K9/0024 Primary

  Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue (compositions for intravenous administration, normal injectable solutions or dispersions for, e.g. subcutaneous administration A61K9/0019; brain implants A61K9/0085; (coated) prostheses, catheters or stents A61L) · CPC title

• A61F2/06

  Blood vessels · CPC title

• A61L2300/414

  Growth factors · CPC title

• A61L2300/41

  Anti-inflammatory agents, e.g. NSAIDs · CPC title